John Lewicki
Fortuna: 31 932 $ al 31/05/2026
Fortuna: 31 932 $ al 31/05/2026
John A. Lewicki is Chief Scientific Officer at Mereo BioPharma Group Plc since 2020.
Formerly, Dr. Lewicki was President, Chief Executive Officer & Director at Mereo BioPharma 5, Inc. from 2018 to 2019.
Prior to that, Dr. Lewicki was Principal at Scios, Inc. from 1983 to 2000.
Dr. Lewicki earned a doctorate from the University of California San Diego.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 01/02/2026 | 464.130 ( 0,06 % ) | 31 932 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Director Técnico/Científico/I+D | 01/07/2020 |
| Empresas | Cargo | Fin |
|---|---|---|
| ONCOMED PHARMACEUTICALS INC | Director Ejecutivo | 23/04/2019 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures & commercializes pharmaceuticals | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures & commercializes pharmaceuticals | Health Technology |
Mereo BioPharma 5, Inc.
Mereo BioPharma 5, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-cancer stem cell therapeutics | Health Technology |
University of California San Diego
University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mereo BioPharma Group Plc
Mereo BioPharma Group Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.